Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138528

Published: 2020

Journal Articles

Sequential Infusion of Tcrαβ- and CD45RA-Depleted Haploidentical Progenitor Cells Is Safe and Allows for Rapid Immune Reconstitution in Pediatric Patients with Recurrent Hematological Malignancies

Ali Y Suliman, MD MSc, Ying Li, MD PhD, David Cullins, Amanda J Sooter, Janice Riberdy, PhD, Madden Renee, MD, Ewelina Mamcarz, MD, Amr Qudeimat, MD, Akshay Sharma, MBBS, Ashok Srinivasan, MD, Aimee Talleur, MD, Anusha Sunkara, MS, Guolian Kang, PhD, Stephen Gottschalk, MD, Brandon Triplett, MD

Blood (2018) 132 (Supplement 1): 4574.

https://doi.org/10.1182/blood-2018-99-110886

Published: 2018

Journal Articles

A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Maxim Norkin, MD PhD, Myron Chang, PhD, An Qi, PhD, Helen Leather, BPharm, Lakshmikanth Katragadda, MD, Ying Li, MD PhD, Jan S Moreb, MD, W. Stratford May, MD PhD, Randy A. Brown, MD, Jack W. Hsu, MD, John W Hiemenz, MD, John R Wingard, MD, Christopher R. Cogle, MD

Blood (2015) 126 (23): 3852.

https://doi.org/10.1182/blood.V126.23.3852.3852

Published: 2015

Journal Articles

Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes

Lakshmikanth Katragadda, MD, Maxim Norkin, MD PhD, Myron Chang, PhD, Yunfeng Dai, PhD, Jan S Moreb, MD, W. Stratford May, MD PhD, Christopher R. Cogle, MD, Helen Leather, BPharm, Ying Li, MD PhD, Lamis K Eldjerou, MD, John W Hiemenz, MD, Randy A. Brown, MD, John R. Wingard, MD

Blood (2015) 126 (23): 3221.

https://doi.org/10.1182/blood.V126.23.3221.3221

Published: 2015

Journal Articles

Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows

Maxim Norkin, MD, PhD, Jan Moreb, MD, Helen Leather, BPharm, Randy A. Brown, MD, Jack W. Hsu, MD, John W Hiemenz, MD, W. Stratford May, MD, PhD, Myron N Chang, PhD, Qi An, Ying Li, MD, PhD, Christopher R Cogle, MD, John R Wingard, MD

Blood (2013) 122 (21): 1412.

https://doi.org/10.1182/blood.V122.21.1412.1412

Published: 2013

Journal Articles

Expression of JAZ in Multiple Myeloma and Its Potential Role as A Novel Molecular Target.

Mingli Yang, PhD, Jingxin Qiu, MD, PhD, Ying Li, MD, PhD, David Ostrov, PhD, Jinghua Jia, PhD, W. Stratford May, MD, PhD

Blood (2009) 114 (22): 2862.

https://doi.org/10.1182/blood.V114.22.2862.2862

Published: 2009

NARROW

Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience

Sequential Infusion of Tcrαβ- and CD45RA-Depleted Haploidentical Progenitor Cells Is Safe and Allows for Rapid Immune Reconstitution in Pediatric Patients with Recurrent Hematological Malignancies

A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes

Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows

Expression of JAZ in Multiple Myeloma and Its Potential Role as A Novel Molecular Target.

Email alerts

ASH Publications

American Society of Hematology

Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience

Sequential Infusion of Tcrαβ- and CD45RA-Depleted Haploidentical Progenitor Cells Is Safe and Allows for Rapid Immune Reconstitution in Pediatric Patients with Recurrent Hematological Malignancies

A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes

Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows

Expression of JAZ in Multiple Myeloma and Its Potential Role as A Novel Molecular Target.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only